Back to Stakeholders
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchIndependent Academic Research Groups
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & Manufacturing

Cessatech A/S

Denmark
1 Trial

Cessatech A/S is a Copenhagen-based paediatric biotech developing CT001, a first-in-class intranasal ketamine/sufentanil combination analgesic for acute pain in children aged 1–17, with an EMA Marketing Authorisation Application submitted in 2025 and approval expected in 2026.

Academic Research

0 papers

Published Papers

0

Trial Involvement

1

Distinct Focus Topics

0

Latest Publication

Unknown

Quick Facts

Type
Public Biotech
HQ
Denmark
Website
Visit

Sponsored Trials

1
CompletedII, III

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients

Start Date